Target intelligence / Profile preview

Polynucleotide 5'-hydroxyl-kinase NOL9 (NOL9)

Target
NOL9
Molecular classification
Enzyme (Specifically, Polynucleotide kinase), RNA-binding protein, Non-ribosomal nucleolar protein
01

Overview

Polynucleotide 5'-hydroxyl-kinase NOL9 (NOL9) is a non-ribosomal nucleolar enzyme that catalyzes the phosphorylation of the 5'-hydroxyl groups on RNA and DNA strands, a critical step in the maturation of ribosomal RNA. NOL9 preferentially associates with pre-60S ribosomal particles, and its kinase activity is necessary for efficient processing of large ribosomal subunit rRNAs, particularly facilitating conversion of precursor 32S rRNA into mature 5.8S(S) and 28S rRNAs. It forms a functional complex with LAS1L, combining endonuclease and kinase activities to mediate pre-rRNA cleavage and maturation. NOL9 is essential for ribosome biogenesis, cell proliferation, and normal development, as established by loss-of-function studies in animal models. Mutations or dysregulation of NOL9 are linked to rare genetic diseases and may play a role in cancer and ribosomopathies. No therapeutically approved drugs directly target NOL9, and inhibition would likely have broad and severe biological consequences due to its fundamental role in ribosome formation[1][2][3][5][6].

Other names
Nucleolar protein 9NET6Grc3FLJ23323polynucleotide 5'-hydroxyl-kinase NOL9polynucleotide 5'-kinase
02

Mechanism of action

Theoretical: Inhibition of NOL9 would interfere with the phosphorylation step in rRNA processing, resulting in defective ribosome biogenesis and altered protein synthesis[1][3][5].

03

Biological functions

Phosphorylation of 5'-hydroxyl groups of single- and double-stranded RNA and DNA substratesRibosomal RNA (rRNA) processing (essential for maturation of 5.8S and 28S rRNAs, especially for generating the major 5.8S(S) form)Formation of endonuclease-kinase complexes with LAS1L, crucial in ITS2 pre-rRNA processingTransport of pre-rRNA processing complexes to the nucleolus
04

Disease associations

Familial hyperaldosteronism, type IShwachman-Diamond syndrome 1Essential for normal development (mutation leads to developmental defects in model organisms)Implicated in cancer and cell proliferation via ribosome biogenesis
05

Safety considerations

Targeting NOL9 may cause defects in ribosome biogenesis and consequential severe downstream effects such as impaired cell growth and proliferation, toxicity in dividing tissues

Beyond the preview

Go deeper on Polynucleotide 5'-hydroxyl-kinase NOL9 (NOL9).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polynucleotide 5'-hydroxyl-kinase NOL9 (NOL9).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call